Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit.

24 May 2016

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, a pediatric oncologist from Dana-Farber/Boston Children's Cancer and Blood Disorders Center argues in an editorial published today by the journal Pediatrics.

23 May 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016.

20 May 2016

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth.

20 May 2016

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer.

20 May 2016

Loss of HOXA5 protein may allow breast cancer cells to thrive

Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.

20 May 2016

Radiation-immunotherapy combination can help treat melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in a review article.

20 May 2016

Study explores whether way of expressing condolences should be standardised among oncologists

The results of a new survey published in ecancermedicalscience indicate that a majority of oncology professionals believe that writing condolence letters to the families of deceased patients is an important component of cancer palliative care.

20 May 2016

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits.

19 May 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

19 May 2016

Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

A new study shows that repeated radiation therapy used to target tumors in the brain may not be as safe to healthy brain cells as previously assumed.

19 May 2016

$Allogeneic HSCT offers good survival for select TKI-refractory CML patients$

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests.

18 May 2016

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study.

18 May 2016

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators.

18 May 2016

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy.

18 May 2016

Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

overview of Medopad and how you deliver patient information to mobile devices? Medopad is a mobile health technology company. We focus on developing software within the mobile health industry. Mobile health, from our perspective, is an industry that really was invented with the iPad.

18 May 2016

Motor protein Myo1c uses actin cytoskeleton as 'track' for Neph1 transport

The motor protein Myo1c binds to Neph1, a protein crucial for ensuring effective filtration by the kidney, and serves as one mode of its cellular transport, according to findings by investigators at the Medical University of South Carolina and their collaborators reported in the May 16, 2016 issue of Molecular and Cellular Biology.

17 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Among the women inducted into the University of Kansas Hall of Fame on April 14, 2016, was Carol Fabian, MD. Fabian, a professor of medicine at the University of Kansas Medical Center and director of the Breast Cancer Prevention Center at The University of Kansas Cancer Center, is a nationally recognized oncologist and a pioneer in in the field of breast cancer research.

17 May 2016

Oncology News and Research

Further Reading

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Phase I study of triple drug combination shows promise in multiple myeloma patients

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Loss of HOXA5 protein may allow breast cancer cells to thrive

Radiation-immunotherapy combination can help treat melanoma

Study explores whether way of expressing condolences should be standardised among oncologists

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

Tecentriq drug gets FDA approval to treat urothelial carcinoma

Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

Empowering mobile health: an interview with Dr Rich Khatib and Dan Vahdat

Motor protein Myo1c uses actin cytoskeleton as 'track' for Neph1 transport

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Carol Fabian inducted into KU Women's Hall of Fame for contributions to breast cancer research

Your guide to microplate readers for cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News